LLY rebounds into a buy range, securing spots on IBD Leaderboard and Big Cap 20 screens amid market rotation into healthcare.
Eli Lilly (LLY) has re-entered a buy zone as the Nasdaq composite rebounds from Friday’s sell-off. The stock’s relative strength line is rising, positioning it on Investor’s Business Daily’s Leaderboard, Big Cap 20, and Stock Spotlight screens.
The move follows a broader market rotation into healthcare, with LLY leading medical stocks. The Nasdaq’s recent volatility had pressured equities, but defensive sectors like pharmaceuticals are showing resilience.
No immediate market reaction data was provided, but the inclusion in IBD screens suggests investor interest in large-cap health stocks.